KBI BioPharma Advances Proprietary Bioprocessing Technology Into Applied Biopharmaceutical Development
Durham. -KBI BioPharma, Inc., a contract biopharmaceutical process development, production and technology company, announced the advancement of its proprietary Centrifugal Bioreactor (CBR) technology from a research environment into an applied development phase.
Proof-of-principle work has demonstrated that the CBR technology represents a highly productive cell culture system, capable of maintaining extremely high density fluidized bed cultures of both prokaryotic and eukaryotic cells over long periods. The system has been demonstrated to be robust in a laboratory setting and to be compatible with most recognized biopharmaceutical production cell lines. KBI BioPharma will now focus its efforts on demonstrating high productivity of a number of specific recombinant protein and monoclonal antibody products in an applied development environment.
"We are extremely pleased to be able to advance this important biopharmaceutical production technology from a research setting into applications development," said Tony Laughrey, chief executive officer and president of KBI BioPharma. "We believe that the CBR has the potential to dramatically reduce the cost of production for biopharmaceuticals for both clinical trial quantities and market supply and may represent a paradigm changing approach to production of these important molecules."
All future CBR development work will be undertaken within laboratories at KBI BioPharma's campus in Durham, N.C., where the company's established biopharmaceutics platform will be leveraged to facilitate rapid progression through applications development. KBI BioPharma's highly experienced development staff, cGMP infrastructure, state-of-the-art analytical capabilities and quality expertise will be utilized in support of further development under the direction of Dr. Firoz Mistry, vice president cell culture and fermentation operations.
KBI BioPharma's CBR technology applies advanced fluidized bed methodology to allow cells producing recombinant therapeutic and vaccine products to be immobilized at very high densities without use of membranes or other solid support or retention devices. CBR technology allows true continuous production of uniform high quality product at significantly lower capital and operating cost. KBI BioPharma will execute research collaborations with a limited number of companies developing recombinant proteins or monoclonal antibodies to demonstrate performance of the CBR technology in production of specific products. Interested parties can contact KBI BioPharma's business development group by visiting www.kbibiopharma.com.
Other news from the department research and development
These products might interest you
Hydrosart® Ultrafilter by Sartorius
Efficient ultrafiltration for biotech and pharma
Maximum flow rates and minimum protein loss with Hydrosart® membranes
Hydrosart® Microfilter by Sartorius
Hydrophilic microfilters for bioprocesses
Minimal protein adsorption and high flow rates
Sartobind® Rapid A by Sartorius
Efficient chromatography with disposable membranes
Increase productivity and reduce costs with fast cycle times
Sartopore® Platinum by Sartorius
Efficient filtration with minimal protein adsorption
Reduces rinsing volume by 95 % and offers 1 m² filtration area per 10"
Polyethersulfone Ultrafilter by Sartorius
Reliable filtration with PESU membranes
Perfect for biotechnology and pharmaceuticals, withstands sterilisation and high temperatures
Polyethersulfone Microfilter by Sartorius
Biotechnological filtration made easy
Highly stable 0.1 µm PESU membranes for maximum efficiency
Get the life science industry in your inbox
From now on, don't miss a thing: Our newsletter for biotechnology, pharma and life sciences brings you up to date every Tuesday and Thursday. The latest industry news, product highlights and innovations - compact and easy to understand in your inbox. Researched by us so you don't have to.
Most read news
More news from our other portals
See the theme worlds for related content
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
Topic world Antibodies
Antibodies are specialized molecules of our immune system that can specifically recognize and neutralize pathogens or foreign substances. Antibody research in biotech and pharma has recognized this natural defense potential and is working intensively to make it therapeutically useful. From monoclonal antibodies used against cancer or autoimmune diseases to antibody-drug conjugates that specifically transport drugs to disease cells - the possibilities are enormous
